Literature DB >> 31392164

Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale.

Ramy Sedhom1, Emmanuel S Antonarakis1.   

Abstract

Entities:  

Year:  2019        PMID： 31392164      PMCID： PMC6642951          DOI： 10.21037/tau.2019.05.02

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN： 2223-4683


× No keyword cloud information.
  19 in total

1.  Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.

Authors:  Charles J Ryan; Shreya Shah; Eleni Efstathiou; Matthew R Smith; Mary-Ellen Taplin; Glenn J Bubley; Christopher J Logothetis; Thian Kheoh; Christine Kilian; Christopher M Haqq; Arturo Molina; Eric J Small
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 2.  Clinical features of metastatic bone disease and risk of skeletal morbidity.

Authors:  Robert E Coleman
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

3.  Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice.

Authors:  Jamil Asselah; Catherine Sperlich
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

4.  Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007).

Authors:  Mette Nørgaard; Annette Østergaard Jensen; Jacob Bonde Jacobsen; Kara Cetin; Jon P Fryzek; Henrik Toft Sørensen
Journal:  J Urol       Date:  2010-05-16       Impact factor: 7.450

5.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

6.  Relation between pain and skeletal metastasis in patients with prostate or breast cancer.

Authors:  Gabriella Levren; May Sadik; Peter Gjertsson; Milan Lomsky; Annika Michanek; Lars Edenbrandt
Journal:  Clin Physiol Funct Imaging       Date:  2010-11-28       Impact factor: 2.273

7.  Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases.

Authors:  Nanda K Thudi; Chelsea K Martin; Sridhar Murahari; Sherry T Shu; Lisa G Lanigan; Jillian L Werbeck; Evan T Keller; Laurie K McCauley; Joseph J Pinzone; Thomas J Rosol
Journal:  Prostate       Date:  2010-10-18       Impact factor: 4.104

8.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

9.  Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices.

Authors:  Stephen J Freedland; Akshara Richhariya; Huei Wang; Karen Chung; Neal D Shore
Journal:  Urology       Date:  2012-06-27       Impact factor: 2.649

10.  Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.

Authors:  Emmanuel S Antonarakis; Mario A Eisenberger
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544
View more
  3 in total

Review 1.  Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis.

Authors:  Daniel E Hagaman; Jossana A Damasco; Joy Vanessa D Perez; Raniv D Rojo; Marites P Melancon
Journal:  Molecules       Date:  2021-01-13       Impact factor: 4.411

2.  Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study.

Authors:  Raymond S McDermott; John Greene; John McCaffrey; Imelda Parker; Sylva Helanova; Anne-Marie Baird; Ausra Teiserskiene; Marvin Lim; Helen Matthews; Olwyn Deignan; John Feeney; Pierre G Thirion; Stephen P Finn; Paul J Kelly
Journal:  Ther Adv Med Oncol       Date:  2021-09-06       Impact factor: 8.168

3.  Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.

Authors:  Neal Shore; Celestia S Higano; Daniel J George; Cora N Sternberg; Fred Saad; Bertrand Tombal; Kurt Miller; Jan Kalinovsky; XiaoLong Jiao; Krishna Tangirala; Oliver Sartor
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-05-13       Impact factor: 5.455
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.